The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of these therapies have gone on to blockbuster sales.
Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.
To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in oncology prevention, diagnosis, therapy and care over recent
Cancer immunotherapy is revolutionising oncology – but the Havas Lynx Group’s chief medical officer Vernon Bainton argues that the incredible progress is creating a new
Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunothera
